Search clinical trials for: CART BCMA or CART BCMA huCART19

Total 410 results

University of Pennsylvania
Novartis

Active, not recruiting

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Multiple Myeloma

United States
Shanghai Simnova Biotechnology Co.,Ltd.

Active, not recruiting

Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

China
Bioray Laboratories
The First Affiliated Hospital of Zhengzhou University; Second Xiangya Hospital...

Withdrawn

Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma

Multiple Myeloma

China
Bioray Laboratories
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Efficacy and Safety Evaluation of PD1-BCMA-CART

Multiple Myeloma

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Second Affiliated Hospital of Suzhou University

Unknown

Clinical Trial of BCMA CAR T Cell Infusion in Patients With BCMA-positive r/r Multiple Myeloma

Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Multiple Myeloma | New Diagnosis Tumor

China
University College, London

Active, not recruiting

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Multiple Myeloma | Plasma Cell Leukemia

China
Hrain Biotechnology Co., Ltd.
Shanghai Changzheng Hospital

Recruiting

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects With R/R MM

Multiple Myeloma

China
Sheba Medical Center

Recruiting

Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma

Multiple Myeloma | Relapse Multiple Myeloma

Israel
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Vasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS Syndrome

China
Southwest Hospital, China

Unknown

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia | Multiple Myeloma

China
Hrain Biotechnology Co., Ltd.
First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...

Recruiting

Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM

Multiple Myeloma

China
Ting Chang, MD

Not yet recruiting

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

Myasthenia Gravis

China
Shenzhen University General Hospital

Recruiting

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Multiple Myeloma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Wuhan Union Hospital, China

Not yet recruiting

Study of SYS6020 in BCMA-positive Multiple Myeloma

Multiple Myeloma
Asclepius Technology Company Group (Suzhou) Co....

Unknown

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Multiple Myeloma

China
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Clinical Study of the Safety and Efficacy of BCMA CAR-NK

Multiple Myeloma | Immunotherapy

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma

Multiple Myeloma

China
Allife Medical Science and Technology Co., Ltd.

Unknown

Study of BCMA CAR-T in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd

Recruiting

Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma

Multiple Myeloma in Relapse

China
National Institute of Allergy and Infectious Diseases...
University of Pennsylvania Clinical Cell and Vaccine Production Facility...

Recruiting

CAR-T Cell Therapy for Desensitization in Kidney Transplantation

Kidney Failure | End Stage Renal Failure on Dialysis | Kidney Transplant

United States
Xuzhou Medical University

Recruiting

Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

Multiple Myeloma

China
University of Pennsylvania

Completed

CART-BCMA Cells for Multiple Myeloma

Multiple Myeloma

United States
Lingli Dong
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Lupus Nephritis | ANCA Associated Vasculitis

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Technische Universität Dresden
German Cancer Research Center

Recruiting

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies (CARLOTTA01)

Neoplasms | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Germany
Xijing Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
RenJi Hospital
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

CAR-T Cell Therapy

China
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

CAR-T

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Autoimmune Diseases | Lupus Nephritis | Immune Nephritis

China
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Autoimmune Diseases | Scleroderma

China
Poseida Therapeutics, Inc.
Roche-Genentech

Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM)

Multiple Myeloma

United States
Poseida Therapeutics, Inc.
California Institute for Regenerative Medicine (CIRM)

Terminated

P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Autoimmune Diseases | Sjogren's Syndrome

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Autoimmune Diseases | Systemic Lupus Erythematosus

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
The First Affiliated Hospital of Nanchang University

Unknown

Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Chinese PLA General Hospital

Unknown

Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
CARsgen Therapeutics Co., Ltd.
Xiangya Hospital of Central South University; Peking University People's Hospital and other collaborators

Active, not recruiting

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)

Multiple Myeloma

China
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Henan Cancer Hospital

Unknown

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)

Relapsed and Refractory Multiple Myeloma

China
RenJi Hospital
AbelZeta Pharma Inc.

Recruiting

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy (CAR-AID)

Systemic Lupus Erythematosus (SLE) | Neuromyelitis Optica Spectrum Disorders | Immune-Mediated Necrotizing Myopathy | Multiple Sclerosis-Relapsing-Remitting

China
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China

Search clinical trials for: CART BCMA or CART BCMA huCART19

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations